Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Jefferies Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies Analyst Ratings
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Intra-Cellular Therapies Raised to Overweight From Neutral by Piper Sandler
Intra-Cellular Therapies Analyst Ratings
Piper Sandler Upgrades Intra-Cellular Therapies(ITCI.US) to Buy Rating, Raises Target Price to $92
Intra-Cellular Therapies Analyst Ratings
J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $81
CCORF Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $113
Intra-Cellular Therapies: A Buy Rating on Strong Commercial Performance and Robust Pipeline
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)
Buy Rating Affirmed for Intra-Cellular Therapies Amid Strong Sales and Expansion Potential
Intra-Cellular Therapies Price Target Cut to $74.00/Share From $77.00 by Goldman Sachs
RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)
Buy Rating Affirmed for Intra-Cellular Therapies Amidst Strong Q2 Sales and Strategic Growth Initiatives
Intra-Cellular Therapies Analyst Ratings
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100
Morgan Stanley Remains a Buy on Intra-Cellular Therapies (ITCI)